These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 22916600

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract] [Full Text] [Related]

  • 4. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
    Macías J, Neukam K, Portilla J, Iribarren JA, de Los Santos I, Rivero A, Márquez M, Delgado M, Téllez F, Merino D, Giner L, von Wichmann MA, Pineda JA, HEPRAL study team.
    J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
    [Abstract] [Full Text] [Related]

  • 5. [Integrase inhibition].
    Bogner JR.
    MMW Fortschr Med; 2009 Apr 30; 151(18):68-71. PubMed ID: 19769082
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar 30; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.
    Ann N Y Acad Sci; 2011 Mar 30; 1222():83-9. PubMed ID: 21434946
    [Abstract] [Full Text] [Related]

  • 15. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J, Degen O.
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract] [Full Text] [Related]

  • 16. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
    Warpakowski A.
    MMW Fortschr Med; 2011 May 05; 153(18):50-1. PubMed ID: 21604599
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic hepatitis B].
    Mauss S.
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():48-51. PubMed ID: 19031564
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009 Apr 28; 21(3):3-4. PubMed ID: 19623725
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.